法国 Glivec 四期研究中接受治疗的慢性髓性白血病儿童的早期分子反应的影响。
Impact of early molecular response in children with chronic myeloid leukemia treated in the French Glivec phase 4 study.
机构信息
Centre d'Investigation Clinique 1402 INSERM, Centre Hospitalier Universitaire de Poitiers, Poitiers, France;
Pediatric Department, Assistance Publique-Hôpitaux de Paris and University Paris Diderot, Assistance Publique-Hôpital Saint Louis and Robert Debré, Paris, France;
出版信息
Blood. 2014 Oct 9;124(15):2408-10. doi: 10.1182/blood-2014-05-578567. Epub 2014 Aug 28.
Studies in adults have shown that an early molecular response to imatinib predicts clinical outcome in chronic myeloid leukemia (CML). We investigated the impact of the BCR-ABL1 transcript level measured 3 months after starting imatinib in a cohort of 40 children with CML. Children with a BCR-ABL1/ABL ratio higher than 10% at 3 months after the start of imatinib had a larger spleen size and a higher white blood cell count compared with those with BCR-ABL1/ABL ≤10%. Children with BCR-ABL1/ABL ≤10% 3 months after starting imatinib had higher rates of complete cytogenetic response and major molecular response at 12 months compared with those with BCR-ABL1/ABL >10%. With a median follow-up of 71 months (range, 22-96 months), BCR-ABL1/ABL ≤10% correlated with better progression-free survival. Thus, early molecular response at 3 months predicts outcome in children treated with imatinib for CML. This trial was registered at www.clinicaltrials.gov as #NCT00845221.
研究表明，成人中伊马替尼早期的分子反应可预测慢性髓性白血病（CML）的临床结果。我们研究了在 40 名 CML 患儿队列中，伊马替尼开始后 3 个月测量的 BCR-ABL1 转录本水平对其的影响。与 BCR-ABL1/ABL≤10%的患儿相比，伊马替尼开始后 3 个月 BCR-ABL1/ABL 比值高于 10%的患儿脾脏更大，白细胞计数更高。伊马替尼开始后 3 个月 BCR-ABL1/ABL≤10%的患儿在 12 个月时完全细胞遗传学缓解和主要分子缓解的比例高于 BCR-ABL1/ABL＞10%的患儿。中位随访时间为 71 个月（范围，22-96 个月），BCR-ABL1/ABL≤10%与无进展生存时间更长相关。因此，伊马替尼治疗 CML 的患儿中，3 个月时的早期分子反应可预测结果。该试验在 www.clinicaltrials.gov 上注册，编号为 #NCT00845221。
Zotero 插件